Synergenetics Bioscience

Alpha9 Theranostics is a leading clinical-stage radiopharmaceutical company based in Vancouver, BC, focused on advancing a distinctive portfolio of molecules designed to treat cancer cells with unparalleled precision. By harnessing the power of radiopharmaceuticals, Alpha9 is not only enhancing cancer care but also illuminating new possibilities in precision medicine. The company employs a bespoke iterative process to optimize each component of its molecules, including binders, linkers, chelators, and radioisotopes, supported by state-of-the-art infrastructure and in-house formulation expertise. With a leadership team boasting decades of experience in oncology drug development, Alpha9 is backed by top-tier investors and founders with extensive knowledge in the field of radiopharmaceuticals. Generated from the website

Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeutic and commercial potential, and has generated over $10B in recent M&A, financings, and product launches and are expected to comprise 70% of the $30B nuclear medicine market by 2030. It was launched by adMare BioInnovations, Canada's global life sciences venture, in partnership with industry leaders AbCellera, and some of the country's most successful scientist entrepreneurs.

Alpha9 Theranostics is a leading clinical-stage radiopharmaceutical company based in Vancouver, BC, focused on advancing a distinctive portfolio of molecules designed to treat cancer cells with unparalleled precision. By harnessing the power of radiopharmaceuticals, Alpha9 aims to illuminate new possibilities in precision medicine and improve cancer care outcomes for patients. The company employs a bespoke iterative process to optimize each component of its molecules, including binders, linkers, chelators, and radioisotopes, supported by state-of-the-art infrastructure and in-house formulation expertise. Backed by a leadership team with decades of experience in oncology drug development, Alpha9 is committed to advancing its robust clinical pipeline of radiopharmaceuticals. Generated from the website